Overview

Baricitinib Therapy in COVID-19

Status:
Completed
Trial end date:
2020-04-07
Target enrollment:
Participant gender:
Summary
Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fabrizio Cantini
Treatments:
Lopinavir
Ritonavir